Redeye comments on Dala Energi’s Q2 report, which was again characterised by the strategic restructu...
Redeye updates on GiG Software after Q2-results which were in line with expectations.
The offering represents a 55% discount from yesterday's trading, and we find that Hargreaves has no ...
Redeye updates its estimates following Fable Media Group’s Q2 report, which came in largely in line ...
Redeye notes that Systemair is posting solid Q1 numbers with some minor deviations to our estimates.
Alzinova is a Sweden-based clinical-stage biopharmaceutical company seeking to advance treatments fo...
Redeye comments on Jumpgate’s Q2 report, which was broadly in line with our estimates, with the exce...
Redeye comments on MindArk’s Q2 results, which came in stronger than expected.
Train Alliance levererade ett starkt andra kvartal med stigande intäkter och en förbättrad rörelsema...
Redeye comments on GiG’s Q2-results which were in line with expectations and the preliminary outcome...
VibroSense redovisade en nettoomsättning om 0,27 MSEK (0,55) i kvartalet, motsvarande en minskning m...
Redeye is impressed by the strong delivery from GomSpace during the last two quarters, posting stell...
Redeye initiates coverage of BICO, a leading player in the bioconvergence space.
Redeye provides a research update on Faron Pharmaceuticals following the company’s recent H1 report.
* Europe and other markets continue to perform, North America less so * We reset our expectations-po...
